Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kaulfuss

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Urologie (Heidelberg, Germany)|August 27, 2024
[Sex-specific differences in surgical confidence: results of the Endo Workshop of the German Society of Residents in Urology 2022]Carolin Siech, Luis A Kluth, Mareen Konopka, et al.
Haematologica|April 4, 2020
Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemiaAnuhar Chaturvedi, Charu Gupta, Razif Gabdoulline, et al.
Leukemia|August 1, 2020
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study resultsMichael Heuser, Neil Palmisiano, Ioannis Mantzaris, et al.
Nature Genetics|February 26, 2008
Mutations in the cyclin family member FAM58A cause an X-linked dominant disorder characterized by syndactyly, telecanthus and anogenital and renal malformationsSheila Unger, Detlef Böhm, Frank J Kaiser, et al.
Nature Cancer|August 23, 2024
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor modelsUlrike Rauh, Guo Wei, Michael Serrano-Wu, et al.
Oncogene|March 21, 2017
The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERα-negative breast cancerV Thewes, R Simon, M Hlevnjak, et al.
Acta Neuropathologica|January 27, 2017
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivoStefan Pusch, Sonja Krausert, Viktoria Fischer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2021
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid TumorsAntje Wick, Oliver Bähr, Martin Schuler, et al.
Leukemia|February 25, 2017
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivoA Chaturvedi, L Herbst, S Pusch, et al.
Cell Chemical Biology|March 27, 2024
Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signalingKeith Graham, Philip Lienau, Benjamin Bader, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Urologie (Heidelberg, Germany)|August 27, 2024
[Sex-specific differences in surgical confidence: results of the Endo Workshop of the German Society of Residents in Urology 2022]Carolin Siech, Luis A Kluth, Mareen Konopka, et al.
Haematologica|April 4, 2020
Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemiaAnuhar Chaturvedi, Charu Gupta, Razif Gabdoulline, et al.
Leukemia|August 1, 2020
Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study resultsMichael Heuser, Neil Palmisiano, Ioannis Mantzaris, et al.
Nature Genetics|February 26, 2008
Mutations in the cyclin family member FAM58A cause an X-linked dominant disorder characterized by syndactyly, telecanthus and anogenital and renal malformationsSheila Unger, Detlef Böhm, Frank J Kaiser, et al.
Nature Cancer|August 23, 2024
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor modelsUlrike Rauh, Guo Wei, Michael Serrano-Wu, et al.
Oncogene|March 21, 2017
The branched-chain amino acid transaminase 1 sustains growth of antiestrogen-resistant and ERα-negative breast cancerV Thewes, R Simon, M Hlevnjak, et al.
Acta Neuropathologica|January 27, 2017
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivoStefan Pusch, Sonja Krausert, Viktoria Fischer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2021
Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid TumorsAntje Wick, Oliver Bähr, Martin Schuler, et al.
Leukemia|February 25, 2017
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivoA Chaturvedi, L Herbst, S Pusch, et al.
Cell Chemical Biology|March 27, 2024
Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signalingKeith Graham, Philip Lienau, Benjamin Bader, et al.
Pageof 10